• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Managed Healthcare Executive® State of Industry Survey: Agreement with State Regulation of PBMs

Article

Almost two-third of the respondents to our survey were in favor of the trend of more state-level regulation of the pharmacy benefit management industry.

PBMs have come in for a lot of criticism, and an industry labeled a “middleman” isn’t going to garner a lot of popular support. But federal regulation of the PBM industry hasn’t gone very far. Increasingly, though, state legislatures and agencies are imposing new rules on PBMs. State regulation got a major legal boost in late 2020 when the Supreme Court ruled in Rutledge v. Pharmaceutical Care Management Association that Arkansas could impose requirements on PBMs.

“The bills filed or passed this year concern the licensing or registration of PBMs, requirements for more transparency in the drug supply chain, and protections for independent pharmacies, which have long complained that PBM practices force them into exploitative arrangements,” the Pew Charitable Trusts reported last year.

The clear majority of the respondents to our State of the Industry survey are in favor of the trend in state regulation.

Nearly two-thirds (65%) indicated that they were in favor of increased state oversight and regulation of PBMs. Ninety-one of the 100 respondents answered that question.

We also asked about specific state regulations. The results to those questions were not included in our print issue because of space constraints. They showed agreement with the many of the rules and regulations that have been proposed. For example, 73% of strongly or somewhat agreed with disclosure requirements on PBM indirect and direct revenue sources, and 57% agreed with bans on mandatory mail order.

Related Videos
Video 2 - "Addressing Coexisting Conditions: Keys to Comprehensive Diabetes Care"
Video 1 - "The Influence of Social Determinants of Health on Diabetes Care and Outcomes"
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 4 - "Enhancing Patient Understanding and Treatment Adherence"
Video 2 - "Overview of Treatments for Atopic Dermatitis"
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Related Content
© 2024 MJH Life Sciences

All rights reserved.